The inverse relationship between baseline left ventricular ejection fraction and outcome of antiarrhythmic therapy: a dangerous imbalance in the risk-benefit ratio.
Each year, millions of prescriptions are written for antiarrhythmic drug suppression of ventricular arrhythmias. A large portion of these prescriptions are written for patients with asymptomatic, complex ventricular arrhythmias and organic heart disease, termed "potentially malignant" or "potentially lethal." Since arrhythmia suppression in this population is of unproven benefit, we performed the following study: A total of 246 patients (42% with significant left ventricular dysfunction) had complex ventricular arrhythmias, and were treated with one of eight antiarrhythmic drugs (Vaughan Williams classes IA, IB, IC, II, and III). The extent of arrhythmia suppression and the development of serious complications resulting from therapy after 2 weeks was of primary interest. A total of 82 of 246 (33%) maintained adequate (protocol definition) suppression of both ventricular premature beats (VPBs) as well as nonsustained ventricular tachycardia (VT) for 2 weeks, mostly in patients with left ventricular ejection fraction (LVEF) greater than or equal to 40% (p = 0.04 versus LVEF less than 40%). Life-threatening complications of antiarrhythmic therapy occurred most frequently in the 61 patients with an LVEF less than 30% compared to the 185 patients with LVEF greater than or equal to 30% (15% versus 2.1%, p = 0.0005). Suppression of VT was achieved nearly twice as commonly in patients with an LVEF greater than or equal to 30% than in those with an LVEF less than 30% (67% versus 36%; p = 0.0008). Life-threatening complications occurred seven times as frequently in patients presenting with nonsustained VT and an LVEF less than 30% (18% versus 2.3%; p = 0.003).(ABSTRACT TRUNCATED AT 250 WORDS)
Pratt
C M
CM
Dept. of Internal Medicine, Baylor College of Medicine, Houston, TX 77030.
Eaton
T
T
Francis
M
M
Woolbert
S
S
Mahmarian
J
J
Roberts
R
R
Young
J B
JB
D000889:Anti-Arrhythmia Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000139:chemically induced*; D005117:Cardiac Complexes, Premature / Q000188:drug therapy*; D004562:Electrocardiography; D005260:Female; D006333:Heart Failure / Q000139:chemically induced*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D012307:Risk Factors; D013318:Stroke Volume; D013610:Tachycardia / Q000188:drug therapy*; D013997:Time Factors
D000889:Anti-Arrhythmia Agents